6 amlodipine overdose,” Human and Experimental Toxicology, vol. 24, no. 7, pp. 377–381, 2005. [5] B. Bailey, “Glucagon in beta-blocker and calcium channel blocker overdoses: a systemic review,” Journal of Toxicology— Clinical Toxicoogyl, vol. 41, pp. 595–602, 2003. [6] G. K. Isbister, “Delayed asystlic cardiac arrest after diltiazem overdose; resusitation with high dose intravenous calcium,” Emergency Medicine Journal, vol. 19, pp. 355–357, 2002. [7] B. J. Crump, D. W. Holt, and J. A. Vale, “Lack of response to intravenous calcium in severe verapamil poisoning,” The Lancet, vol. 2, no. 8304, pp. 939–940, 1982. [8] Y. M. Lam, H. F. Tse, and C. P. Lau, “Continuous calcium chloride infusion for massive nifedipine overdose,” Chest, vol. 119, no. 4, pp. 1280–1282, 2001. [9] S. I. McFarlane, A. Kumar, and J. R. Sowers, “Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease,” American Journal of Cardiology, vol. 91, no. 12, pp. 30–37, 2003. [10] H. R. Black, “Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data,” American Heart Journal, vol. 147, no. 4, pp. 564–572, 2004. [11] S. W. Smith, K. L. Ferguson, R. S. Hoﬀman, L. S. Nelson, and H. A. Greller, “Prolonged severe hypotension following com- bined amlodipine and valsartan ingestion,” Clinical Toxicology, vol. 46, no. 5, pp. 470–474, 2008. [12] K. Cumpston, M. Mycyk, and E. Pallash, “Failure of hyper- insulinemia/euglycemia therapy in severe diltiazem overdose,” Journal of Toxicology—Clinical Toxicology, vol. 40, pp. 679– 680, 2002. [13] J. A. Kline, C. A. Tomaszewski, J. D. Schroeder, and R. M. Raymond, “Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine,” Journal of Pharmacology and Experimental Therapeutics, vol. 267, no. 2, pp. 744–750, 1993. [14] M. D. Levine and E. Boyer, “Hyperinsulinemia-euglycemia therapy: a useful tool in treating calcium channel blocker poisoning,” Critical Care, vol. 10, no. 4, article 149, 2006. [15] J. Herbert, C. O’Malley, J. Tracey, R Dwyer, and M. Power, “Verapamil overdosage unresponsive to dextrose/insulin ther- apy,” Journal of Toxicology—Clinical Toxicology, vol. 39, pp. 293–294, 2001. [16] C. Jamaty, B. Bailey, A. Larocque, E. Notebaert, K. Sanogo, and J. M. Chauny, “Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies,” Clinical Toxicology, vol. 48, no. 1, pp. 1–27, 2010. [17] A. C. J. M. de Pont, “Extracorporeal treatment of intoxica- tions,” Current Opinion in Critical Care, vol. 13, no. 6, pp. 668– 673, 2007. [18] A. C. Young, L. I. Velez, and K. C. Kleinschmidt, “Intravenous fat emulsion therapy for intentional sustained-release vera- pamil overdose,” Resuscitation, vol. 80, no. 5, pp. 591–593, 2009. [19] M. E. McBrien, S. T. Webb, D. S. Breslin, A. D. Axon, and J. M. Hunter, “Anaphylaxis and anaesthesia,” British Journal of Anaesthesia, vol. 94, no. 4, pp. 547–548, 2005. [20] J. M. Brown, W. Murtha, J. Fraser, and V. Khoury, “Dynamic left ventricular outﬂow tract obstruction in critically ill patients,” Critical Care Resuscitation, vol. 4, no. 3, pp. 170–172, 2002. [21] M. A. Weber, “Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report,” American Journal of Hypertension, vol. 5, no. 12, pp. 247S–251S, 1992. Case Reports in Medicine